The two main players in the global obesity market are Eli Lilly LLY and Novo Nordisk NVO, with their respective GLP-1 ...

Novo Nordisk A/S is suffering from headwinds in its core anti-obesity medications market. Click here to find out why NVO ...

Search trends reveal India’s wellness market shifting from home remedies to prescription weight-loss drugs, clinical ...

Eli Lilly and Company (NYSE:LLY) is one of the top most profitable NYSE stocks to buy now. On August 7, Leerink downgraded ...

Digestion issues, fatigue, and high costs haven’t stopped some from finding power and transformation through GLP-1 medications.

The report was based on Google search patterns in 2024 and has identified five key shifts shaping the health and wellness ...

Eli Lilly's experimental oral pill, orforglipron, shows promise in obesity treatment, with participants experiencing an ...

Danone is introducing an Oikos brand drink targeting US consumers using weight loss medications such as Wegovy.

Here are five oral obesity candidates that, according to Mizuho’s Graig Suvannavejh, could change the weight loss game.

Data reveals rising consumer interest across key areas including function-first wellness, science-backed self-care, and ...

Led by CEO Kevin Hochman—who formerly oversaw similar revivals at Old Spice and KFC—Chili’s has transformed from a ’90s relic ...

A transformative moment in the global fight against obesity has emerged with the announcement of positive topline results ...